<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04456712</url>
  </required_header>
  <id_info>
    <org_study_id>ciprofloxacin and levofloxacin</org_study_id>
    <nct_id>NCT04456712</nct_id>
  </id_info>
  <brief_title>Effect of Ciprofloxacin Versus Levofloxacin on QTc-interval and Dysglycemia</brief_title>
  <official_title>Effect of Ciprofloxacin Versus Levofloxacin on QTc-interval and Dysglycemia in Diabetic and Non-Diabetic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare intravenous levofloxacin and ciprofloxacin regarding their risk on the corrected&#xD;
      QT interval (QTc) prolongation and dysglycemia in diabetic and non-diabetic patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fluoroquinolones represent an important class of antibacterial drug and they are used&#xD;
      worldwide.Fluoroquinolones are classified into generations according to the spectrum of&#xD;
      antimicrobial activities that targeted them.Fluoroquinolones may cause several side effects&#xD;
      as tendon rupture, central nervous toxicity, cardiovascular toxicity, gastrointestinal&#xD;
      toxicity, phototoxicity, disrupted glucose metabolism, skin disorders and hypersensitivity.&#xD;
      Ciprofloxacin, a second generation fluoroquinolone, is one of the most successful and widely&#xD;
      used compounds of fluoroquinolone. On the other hand, levofloxacin is a third generation&#xD;
      fluoroquinolone.&#xD;
&#xD;
      Diabetes mellitus (DM) is chronic disease and a serious of metabolic disorder associated with&#xD;
      the presence of hyperglycemia due to partial or complete insulin deficiency. Diabetes&#xD;
      mellitus is a major risk factor for cardiovascular diseases.&#xD;
&#xD;
      Fluoroquinolone class is associated with cardiac side effects as QTc prolongation. Some&#xD;
      agents of fluoroquinolones were withdrawn from market. However, cardiac adverse effects has&#xD;
      been developed with fluoroquinolones still in market. Members of fluoroquinolones class have&#xD;
      different effects on QT interval. The US FDA suggested that the risk and benefits ratio of&#xD;
      fluoroquinolones should be taken into consideration.&#xD;
&#xD;
      In addition to hyperglycemia events are more common with fluoroquinolones than with other&#xD;
      classes of antibiotics. The food and drug administration (FDA) confirmed the current warning&#xD;
      that fluoroquinolones may cause decrease in blood sugar especially in diabetic patients.&#xD;
      However, other study proved that fluoroquinolones may cause dysglycemic events in diabetic&#xD;
      and non-diabetic patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>fifty diabetic patients received intravenous levofloxacin 750 mg/24 hours. fifty diabetic patients received intravenous ciprofloxacin 400mg/12 hours. fifty non-diabetic patients received intravenous levofloxacin 750 mg/24 hours. fifty non-diabetic patients received intravenous ciprofloxacin 400mg/12 hours.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of ciprofloxacin versus levofloxacin on QTc interval</measure>
    <time_frame>before starting antibiotic, after 24 hours, 72 hours from the first dose and after 72 hours from antibiotic cessation</time_frame>
    <description>change in QTc interval (QTc prolongation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of ciprofloxacin versus levofloxacin on fasting blood glucose</measure>
    <time_frame>before starting antibiotic, after 24 hours, 72 hours from the first dose and after 72 hours from antibiotic cessation</time_frame>
    <description>change in fasting blood glucose (dysglycemia)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>QTc Prolongation, Hyperglycemia, Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>ciprofloxacin for diabetic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 diabetic patients received intravenous ciprofloxacin 400mg/12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levofloxacin for diabetic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 diabetic patients received intravenous levofloxacin 750mg/24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ciprofloxacin for non-diabetic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 non-diabetic patients received intravenous ciprofloxacin 400mg/12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levofloxacin for non-diabetic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 non-diabetic patients received intravenous levofloxacin 750mg/24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin 400 MG/200 ML Intravenous Solution</intervention_name>
    <description>antibiotic</description>
    <arm_group_label>ciprofloxacin for diabetic patients</arm_group_label>
    <arm_group_label>ciprofloxacin for non-diabetic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 750 MG</intervention_name>
    <description>antibiotic</description>
    <arm_group_label>levofloxacin for diabetic patients</arm_group_label>
    <arm_group_label>levofloxacin for non-diabetic patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patient (male, female)&#xD;
&#xD;
          -  age from 18 to 70 years .&#xD;
&#xD;
          -  Be able to give an informed consent form after understanding for reasonable&#xD;
             explanation of clinical trial's purpose, contents and characteristics of clinical&#xD;
             drugs&#xD;
&#xD;
          -  Wiling to participate whole clinical trial periods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Younger than 18 years or older than 70 years.&#xD;
&#xD;
          -  Has prolonged QTc before receiving therapy.&#xD;
&#xD;
          -  With a history of heart diseases.&#xD;
&#xD;
          -  Received class IA or III antiarrhythmic agents.&#xD;
&#xD;
          -  Received macrolide antibiotics.&#xD;
&#xD;
          -  With a history of quinolone allergy.&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed A Elberry, professor</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of medicine, Beni-Suef university, Beni-Suef, Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hazem S Hussein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of medicine, Beni-Suef university, Beni-Suef, Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raghda R Sayed, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of pharmacy, Beni-Suef university, Beni-Suef, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beni-Suef university hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Mathews B, Thalody AA, Miraj SS, Kunhikatta V, Rao M, Saravu K. Adverse Effects of Fluoroquinolones: A Retrospective Cohort Study in a South Indian Tertiary Healthcare Facility. Antibiotics (Basel). 2019 Jul 27;8(3). pii: E104. doi: 10.3390/antibiotics8030104.</citation>
    <PMID>31357640</PMID>
  </reference>
  <reference>
    <citation>Lu ZK, Yuan J, Li M, Sutton SS, Rao GA, Jacob S, Bennett CL. Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf. 2015 Feb;14(2):295-303. doi: 10.1517/14740338.2015.989210. Epub 2014 Dec 10. Review.</citation>
    <PMID>25494485</PMID>
  </reference>
  <reference>
    <citation>Granados J, Ceballos M, Amariles P. [Hypo or hyperglycemia associated with fluoroquinolone use]. Rev Med Chil. 2018 May;146(5):618-626. doi: 10.4067/s0034-98872018000500618. Review. Spanish.</citation>
    <PMID>30148925</PMID>
  </reference>
  <reference>
    <citation>González M C, Rosales C R, Pavez D, Fuenzalida LM, Soto A, Pérez R, Pérez J, Araos R, Pinto ME. [Safety of fluoroquinolones: risks usually forgotten for the clinician]. Rev Chilena Infectol. 2017 Dec;34(6):577-582. doi: 10.4067/S0716-10182017000600577. Spanish.</citation>
    <PMID>29488552</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Nada Abd El-Hamed Saad Rezk</investigator_full_name>
    <investigator_title>clinical pharmacist</investigator_title>
  </responsible_party>
  <keyword>Levofloxacin, ciprofloxacin, QTc prolongation, dysglycemia.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 6, 2020</submitted>
    <returned>July 20, 2020</returned>
    <submitted>July 20, 2020</submitted>
    <returned>August 4, 2020</returned>
    <submitted>August 22, 2020</submitted>
    <returned>September 11, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

